Evoke Pharma
EVOK
#10180
Rank
NZ$32.58 M
Marketcap
NZ$18.92
Share price
-0.09%
Change (1 day)
163.72%
Change (1 year)

P/E ratio for Evoke Pharma (EVOK)

P/E ratio as of December 2025 (TTM): -3.64

According to Evoke Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.6439. At the end of 2017 the company had a P/E ratio of -2.69.

P/E ratio history for Evoke Pharma from 2013 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2017-2.6969.15%
2016-1.59-8.9%
2015-1.75-35.19%
2014-2.69

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Ironwood Pharmaceuticals
IRWD
18.3-601.92%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
47.8-1,410.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Amphastar Pharmaceuticals
AMPH
11.4-412.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Aerie Pharmaceuticals
AERI
-20.3 458.01%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.